Jane Huang

Insider Reports History

Location
Camana Bay
Signature
/s/ Bryant D. Lim, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Jane Huang:

Company Role Class Num Shares Value Price $ Report Date Ownership
BeiGene, Ltd. CMO, Hematology Ordinary Shares 160,055 $33,246,160 $207.72 14 Dec 2021 Direct
Prelude Therapeutics Inc President, CMO Common Stock 86,917 $127,767 $1.47 04 Oct 2025 Direct
Prelude Therapeutics Inc President, CMO Restricted Stock Unit 18,750 $25,969 $0.6925 04 Oct 2025 Direct
BeiGene, Ltd. CMO, Hematology Share Option (Right to Buy) 211,276 14 Dec 2021 Direct
Prelude Therapeutics Inc President, CMO Employee Stock Option (right to buy) 200,000 04 Feb 2025 Direct
Protara Therapeutics, Inc. Director Stock Option (Right to Buy) 24,000 12 Jun 2025 Direct
BeiGene, Ltd. CMO, Hematology American Depositary Shares 0 $180.50 14 Dec 2021 Direct

Insider Reports Filed by Jane Huang

Symbol Company Period Transactions Value $ Form Type Role Filing Time
PRLD Prelude Therapeutics Inc 04 Oct 2025 3 -$4,932 4 President, CMO 07 Oct 2025, 07:05
PRLD Prelude Therapeutics Inc 04 Jul 2025 3 -$2,664 4 President, CMO 08 Jul 2025, 16:06
TARA Protara Therapeutics, Inc. 12 Jun 2025 1 $0 4 Director 13 Jun 2025, 16:05
PRLD Prelude Therapeutics Inc 04 Apr 2025 3 -$2,265 4 President, CMO 07 Apr 2025, 16:11
PRLD Prelude Therapeutics Inc 04 Feb 2025 1 $0 4 President, CMO 05 Feb 2025, 16:31
PRLD Prelude Therapeutics Inc 04 Jan 2025 3 -$5,364 4 President, CMO 07 Jan 2025, 16:15
PRLD Prelude Therapeutics Inc 04 Oct 2024 3 -$6,698 4 President, CMO 07 Oct 2024, 16:10
PRLD Prelude Therapeutics Inc 04 Jul 2024 3 -$12,049 4 President, CMO 08 Jul 2024, 16:02
TARA Protara Therapeutics, Inc. 07 Jun 2024 1 $0 4 Director 10 Jun 2024, 18:00
PRLD Prelude Therapeutics Inc 04 Apr 2024 3 -$15,865 4 President, CMO 08 Apr 2024, 16:11
PRLD Prelude Therapeutics Inc 01 Mar 2024 1 $0 4 President, CMO 04 Mar 2024, 18:01
PRLD Prelude Therapeutics Inc 04 Jan 2024 3 -$14,492 4 President, CMO 08 Jan 2024, 17:00
PRLD Prelude Therapeutics Inc 04 Oct 2023 2 $0 4 President, CMO 06 Oct 2023, 09:07
PRLD Prelude Therapeutics Inc 04 Jul 2023 3 -$15,075 4 President, CMO 06 Jul 2023, 16:35
TARA Protara Therapeutics, Inc. 07 Jun 2023 1 $0 4 Director 08 Jun 2023, 16:10
PRLD Prelude Therapeutics Inc 04 Apr 2023 3 -$81,274 4 President, CMO 06 Apr 2023, 18:19
PRLD Prelude Therapeutics Inc 07 Feb 2023 1 $0 4 President, CMO 09 Feb 2023, 15:07
TARA Protara Therapeutics, Inc. 08 Jun 2022 1 $0 4 Director 09 Jun 2022, 16:10
PRLD Prelude Therapeutics Inc 02 May 2022 2 $0 4 President, CMO 04 May 2022, 17:46
PRLD Prelude Therapeutics Inc 04 Apr 2022 0 $0 3 President, CMO 06 Apr 2022, 16:50
ONC BeiGene, Ltd. 14 Dec 2021 8 -$237,271 4 CMO, Hematology 16 Dec 2021, 16:50
ONC BeiGene, Ltd. 30 Nov 2021 4 -$377,493 4 CMO, Hematology 02 Dec 2021, 17:21
ONC BeiGene, Ltd. 17 Nov 2021 11 -$392,063 4 CMO, Hematology 19 Nov 2021, 17:18
ONC BeiGene, Ltd. 19 Oct 2021 9 -$379,223 4 CMO, Hematology 21 Oct 2021, 17:37
ONC BeiGene, Ltd. 20 Sep 2021 16 -$1,668,014 4 CMO, Hematology 22 Sep 2021, 18:15
ONC BeiGene, Ltd. 13 Sep 2021 8 -$4,620,390 4 CMO, Hematology 15 Sep 2021, 18:16
ONC BeiGene, Ltd. 31 Aug 2021 6 -$346,621 4 CMO, Hematology 02 Sep 2021, 20:39
ONC BeiGene, Ltd. 15 Jul 2021 12 -$3,895,769 4 CMO, Hematology 19 Jul 2021, 16:43
ONC BeiGene, Ltd. 28 Jun 2021 9 -$639,088 4 CMO, Hematology 30 Jun 2021, 16:49
ONC BeiGene, Ltd. 16 Jun 2021 3 -$152,733 4 CMO, Hematology 21 Jun 2021, 16:45
TARA Protara Therapeutics, Inc. 09 Jun 2021 2 $0 4 Director 10 Jun 2021, 21:35
TARA Protara Therapeutics, Inc. 09 Jun 2021 0 $0 3 Director 10 Jun 2021, 21:34
ONC BeiGene, Ltd. 07 Jun 2021 1 -$211,986 4 CMO, Hematology 09 Jun 2021, 16:45
ONC BeiGene, Ltd. 28 May 2021 11 -$686,046 4 CMO, Hematology 02 Jun 2021, 16:40